Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy.
Journal:
European heart journal
Published Date:
Jul 18, 2025
Abstract
BACKGROUND AND AIMS: The diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) requires advanced imaging, precluding large-scale preclinical testing. Artificial intelligence (AI)-enabled transthoracic echocardiography (TTE) and electrocardiography (ECG) may provide a scalable strategy for preclinical monitoring.
Authors
Keywords
No keywords available for this article.